Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (FRA:FDY)

FRA:FDY Revenue

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had revenue of 160.99M CNY in the quarter ending September 30, 2025, with 14.40% growth. This brings the company's revenue in the last twelve months to 711.63M, up 2.89% year-over-year. In the year 2024, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had annual revenue of 709.40M, down -16.61%.

• Revenue (ttm): 711.63M CNY
• Revenue Growth: +2.89%
• P/S Ratio: 10.09
• Revenue / Employee: 791.58K CNY
• Employees: 899
• Market Cap: 859.24M EUR

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	709.40M	-141.33M	-16.61%
Dec 31, 2023	850.73M	-180.43M	-17.50%
Dec 31, 2022	1.03B	-109.15M	-9.57%
Dec 31, 2021	1.14B	306.51M	36.76%
Dec 31, 2020	833.80M	-195.49M	-18.99%